Fierce Biotech16h
Novo inks $1B biobucks Lexicon obesity deal after seeing preclinical prospect shine with semaglutide
Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...
Finanznachrichten18d
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
Bagsværd, Denmark, 10 March 2025 - Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety ...
NBC DFW18d
Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug
Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop ...
Business Insider18d
Novo Nordisk reports REDEFINE 2 trial of CagriSema achieved primary endpoint
Novo Nordisk (NVO) announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly ...
Becker's Hospital Review19d
Novo Nordisk drug yields 15.7% weight loss in phase 3 trial
An experimental obesity drug from Novo Nordisk resulted in 15.7% weight loss after 68 weeks of treatment — falling short of the company’s expectations of 25% weight loss. The subcutaneous ...
BioPharma Dive19d
Novo’s Wegovy successor disappoints in second large trial
While Zepbound has a single main ingredient, CagriSema’s two components can’t be dissolved together, requiring them to be manufactured separately and then delivered with a dual-chambered pen. Novo’s ...
The Australian Financial Review19d
Ozempic maker says its Australian market could be half the population
Gift 5 articles to anyone you choose each month when you subscribe. Danish pharmaceutical giant Novo Nordisk says about 13 million Australians are living with obesity or are overweight ...
The Financial Express22d
Novo Nordisk to launch new therapies in blood and growth disorders after success in diabetes and obesity
Novo Nordisk has become a global sensation with ... disease into innovative medicines and delivery systems, like insulin pens. The company’s disease portfolio includes diabetes, obesity, and ...
Mena FN22d
Insulin Pens Market Report 2024: Segments, Share, Regulatory, Reimbursement And Forecasts To 2036 Featuring Novo Nordisk AS, Eli Lilly And Co, Sanofi
(MENAFN- GlobeNewsWire - Nasdaq) Dublin, March 06, 2025 (GLOBE NEWSWIRE) -- The "Insulin Pens market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2036" report has been added ...
FiercePharma22d
In FDA obesity drug battle with compounders, Texas court allows Novo Nordisk to weigh in
In making his ruling, Pittman wrote that "good cause exists for Novo Nordisk's intervention in this case under Federal Rule of Civil Procedure 24." The rule allows for intervention of a third ...
Yahoo Finance22d
Insulin Pens Market Report 2024: Segments, Share, Regulatory, Reimbursement and Forecasts to 2036 Featuring Novo Nordisk AS, Eli Lilly and Co, Sanofi
Dublin, March 06, 2025 (GLOBE NEWSWIRE) -- The "Insulin Pens Market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2036" report has been added to ResearchAndMarkets.com's offering.